Lactobacillus salivarius for Health & Longevity

Evidence Review created on 09/27/2026 using AI4L + evidence-mcp / GPT 6

Also known as: Ligilactobacillus salivarius, L. salivarius, Lactobacillus salivarius subsp. salivarius, Lactobacillus salivarius subsp. salicinius

Motivation

Lactobacillus salivarius is a species of bacteria found naturally in the human mouth and digestive tract. Selected strains are sold as probiotics, live microbes used with the aim of supporting health. Interest in this species includes its interactions with other bacteria and with the body’s defenses, both of which connect it to questions about maintaining health over time.

The name covers many strains rather than one standardized intervention. Research has examined different preparations in oral health, eczema, and reproductive health, using swallowed capsules, tablets that dissolve in the mouth, and mixtures with other ingredients. Products also differ in whether their bacteria remain alive. The newer name, Ligilactobacillus salivarius, appears alongside the older name in scientific papers and product labeling, adding another layer to understanding exactly what was tested.

This review examines human evidence for benefits and harms, the relevance of experimental research to longevity, and the importance of strain identity, product quality, treatment context, and measurable outcomes for adults actively evaluating health interventions.

Benefits - Risks - Protocol - Conclusion

These sources introduce the organism, strain-specific research, and the wider probiotic claims that surround it.

No verified species-specific item was located from Peter Attia, Andrew Huberman, or Lifespan.io in these searches; broad microbiome material was not substituted for evidence about this organism.

Grokipedia

Ligilactobacillus salivarius

An overview of the species’ taxonomy, habitats, and proposed probiotic properties. Its mechanisms and health applications provide background; individual clinical claims require comparison with the primary studies reviewed here.

Examine

No dedicated Examine article for Lactobacillus salivarius was found as of September 27, 2026. Related-species pages and general probiotic summaries do not provide an equivalent monograph.

ConsumerLab

No dedicated ConsumerLab article for Lactobacillus salivarius was found as of September 27, 2026. Its broader probiotic reviews and product questions include this organism but are not species-specific reviews.

Systematic Reviews

Systematic reviews (structured assessments of available studies) and meta-analyses (statistical pooling of results) cover mastitis (breast inflammation), atopic dermatitis (itchy inflammatory eczema), halitosis (bad breath), prebiotics (microbe-feeding ingredients), pregnancy safety, and experimental carcinogenesis (cancer development), often combining species or formulations.

No species-specific systematic review quantifying supplement-attributable bloodstream infection was located; individual clinical reports and a hospital cohort inform that risk below.

Mechanism of Action

Lactobacillus salivarius, now classified as Ligilactobacillus salivarius, contains genetically distinct strains. It differs from Streptococcus salivarius, including K12 and M18 in some oral products. A species name identifies neither the tested formulation nor its expected activity.

Some strains attach to oral or intestinal surfaces, compete with other microbes, and generate lactic acid or bacteriocins (proteins that inhibit susceptible bacteria). UCC118 produces Abp118: removing this bacteriocin abolished protection against Listeria infection in a mouse experiment. This demonstrates a mechanism, not human infection prevention. Other strains may affect intestinal barriers, immune signaling, or purines (precursors of uric acid), as Neville and O’Toole describe.

Li et al. instead found enhanced pathogen attachment and intestinal injury in laboratory and mouse models; human supplement harm remains unproven.

Cancer findings point in opposing directions. Zhou et al. implicated a metabolite in weakened antitumor defenses, whereas Zhang et al. associated chenodeoxycholic acid (a bile acid) with enhanced immune-based treatment response. The latter includes Shenzhen Xbiome Biotech investigators, a commercial interest. Different cancer settings, bacterial strains, and metabolites may explain disagreement; patient associations and experimental models establish neither benefit nor harm from retail supplements.

Accompanying fiber, other bacteria, or improved oral hygiene can also explain favorable trials. Microbial abundance and inflammatory changes need not imply clinical benefit or persistent colonization.

This live-organism intervention has no established human drug half-life, receptor selectivity, systemic tissue-distribution profile, or liver-enzyme clearance pathway. Local survival, growth, competition, and stool elimination determine exposure. Heat-inactivated preparations are biologically different.

Historical Context & Evolution

L. salivarius was characterized as a naturally occurring bacterium, not originally developed as a longevity treatment. Research subsequently explored its use as a probiotic (a live microorganism administered for a health benefit), including pathogen control in animals and human intestinal or oral applications. Neville and O’Toole’s 2010 review describes this transition from microbial characterization to strain-specific investigation.

Early clinical work did not show uniformly favorable outcomes. In a 2005 trial comparing different probiotics for irritable bowel syndrome (recurrent abdominal discomfort with altered bowel habits), the clear symptom benefit belonged to the tested Bifidobacterium, not L. salivarius UCC4331. A 2008 WB21 oral trial, involving Wakamoto-affiliated investigators, reported improvements concentrated in smokers rather than a universal advantage.

Later trials broadened the clinical questions to eczema, lactation, fertility, and metabolic health. Interest in longevity grew from the connection between microbial ecology, inflammation, and age-related functional decline. However, these connections are not interchangeable with trials of lifespan or prevention of age-related disease.

The 2020 renaming to Ligilactobacillus salivarius changed taxonomy rather than proving additional therapeutic effects. Current interpretation depends on the actual strain, preparation, comparator, and outcome. Positive findings and null results both contribute to this more specific account; neither a favorable mechanism nor a disappointing trial settles the entire species’ potential.

Expected Benefits

Evidence grades refer to the outcome class and replication, not whether the study population resembles a healthy longevity-focused adult. High denotes replicated human clinical outcomes; Medium denotes a single clinical trial; Low denotes indirect, uncontrolled, or conflicting human findings; Speculative denotes mechanisms, animal work, or unvalidated biomarkers. A High grade for a named strain and condition does not establish a species-wide longevity benefit.

Clinical terms used below include gout (joint inflammation from urate crystals), endometriosis (uterine-like tissue outside the uterus), rheumatoid arthritis (inflammatory joint disease), lupus (an immune disease affecting multiple organs), and ulcerative colitis (inflammation and ulcers in the large intestine).

High 🟩 🟩 🟩

Reduced Mastitis Burden During Lactation

Two randomized PS2 trials found fewer mastitis cases, plausibly through local microbial and immune effects. The earlier trial enrolled women with previous mastitis; the multicountry trial involved Danone Nutricia and Probisearch investigators, a commercial conflict. A CECT5713 treatment trial also reported better recovery than heterogeneous antibiotic regimens, but this treatment signal is less secure than the replicated prevention evidence. Benefits concern pregnancy and lactation, not healthier aging generally; proposed antibiotic replacement remains unestablished.

Magnitude: Mastitis occurred in 14/55 versus 30/53 women in the earlier trial, and approximately 6% versus 14% in the later trial, probiotic versus placebo.

Reduced Eczema Severity

Human trials support a reduction in atopic dermatitis (itchy inflammatory eczema) severity with selected preparations. An adult LS01 placebo-controlled trial and a childhood trial adding L. salivarius to the same fermentable fiber used by controls reported improvement. A separate adult LS01–BR03 mixture trial cannot isolate LS01’s contribution. Proposed immune modulation remains incompletely established, and skin-disease improvement does not imply benefit for adults without eczema.

Magnitude: In children, SCORAD (a validated eczema severity score) averaged 27.4 versus 36.3 after eight weeks, intervention versus control. The adult systematic review reports severity improvement without consistently meaningful quality-of-life improvement. Prevention evidence is separate: a CUL61-containing mixture trial, involving commercial firm Cultech investigators, found no reduction in overall eczema at two years (34.1% versus 32.4%), despite fewer secondary allergic-eczema cases (5.3% versus 12.1%). This indirect mixture finding does not support the High treatment grade or identify CUL61’s contribution.

Medium 🟩 🟩

Fertility Outcomes in Unexplained Infertility

A 2025 randomized trial tested CECT5713 in both partners before assisted reproduction. Investigators included Kerry Group employees, creating a commercial conflict. Among 57 completing couples from 70 randomized, live-birth success favored supplementation; proposed reproductive immune changes were not accompanied by major microbial-composition changes. Attrition, small numbers, and a one-sided significance test (testing only the predicted direction) make the result preliminary. It does not establish benefit in fertile couples.

Magnitude: Successful pregnancies resulting in live birth occurred in 13/27 versus 6/30 completing couples: 48.1% versus 20.0%, probiotic versus placebo.

Fewer Gout Episodes

A 30-person randomized pilot tested CECT30632 for six months against an allopurinol treatment strategy in recurrent gout (painful joint inflammation from urate crystals). Some probiotic recipients also needed allopurinol. Bacterial degradation of purines is a plausible mechanism, but the small, unblinded comparison does not establish replacement of optimized urate-lowering treatment. Participants had established disease and high baseline uric acid.

Magnitude: At least one attack occurred in 5/15 versus 13/15 participants; mean serum urate in the probiotic group declined from 9.04 to 7.90 mg/dL.

Relief of Allergic Nasal Symptoms

A 199-child randomized trial found reduced symptoms and medication use in allergic rhinitis (allergy-related nasal inflammation). Immune-cell measurements did not explain the clinical response. Direct evidence in adults and equivalence across retail strains remain unestablished.

Magnitude: Symptoms and medication-use scores favored treatment over 12 weeks; the retrieved abstract provides no numerical between-group score difference.

Increased Bowel-Movement Frequency

A 40-adult randomized trial reported improved defecation frequency with CECT5713 over four weeks. Investigators included Puleva Biotech employees, a commercial interest. Participants were healthy, rather than patients with a diagnosed constipation disorder, and microbial or immune changes were accompanying observations. The finding does not establish treatment of irritable bowel syndrome.

Magnitude: Frequency improved after four weeks at 200 million viable bacteria daily; the retrieved abstract does not report an absolute difference in bowel movements.

A 37-woman placebo-controlled pilot tested CECT30632 alongside dienogest for endometriosis (uterine-like tissue growing outside the uterus). Investigators included Exeltis Germany and OTC Chemo employees, commercial interests. Pain-related quality of life, emotional well-being, and perceived control improved. Proposed changes in estrogen metabolism are preliminary; this was an add-on study, not probiotic monotherapy or a trial in healthy women.

Magnitude: Pain, emotional well-being, and self-control domains favored supplementation; the retrieved abstract gives no numerical between-group quality-of-life difference.

Shorter Hospitalization for Newborn Jaundice

A 300-infant randomized trial tested AP-32 alongside phototherapy (light treatment) for jaundice (yellowing from excess bilirubin). It found shorter treatment and hospitalization, plausibly through altered intestinal bilirubin handling. Investigators included manufacturer Glac Biotech employees. The final analysis excluded some participants, and these newborn-specific findings do not establish an adult health or longevity benefit.

Magnitude: Hospitalization averaged 57.06 versus 64.30 hours for AP-32 versus placebo; the final three-group analysis included 277 infants.

Low 🟩

Gum and Implant-Tissue Health ⚠️ Conflicted

WB21 implant research found less gum inflammation, whereas SGL03 research found no between-group clinical advantage. Oral exposure may suppress some pathogens; small samples, different strains, and concurrent dental care complicate comparisons. Overall, benefit is inconsistent and does not establish prevention of tooth or implant loss.

Magnitude: In the SGL03 trial, pocket depth changed from 2.50 to 2.42 mm within the probiotic group, without a significant advantage over placebo; this is not an attributable treatment effect. Two 2026 Oral S1 orthodontic trials, each enrolling 59 participants, also found benefits, particularly with fixed appliances; effects partly receded after discontinuation.

Bad-Breath Control ⚠️ Conflicted

WB21 improved some odor-gas measurements but not examiner-rated breath versus placebo; a 2024 trial was negative. G60 plus inulin (fermentable fiber) performed better on one gas measurement, unlike G60 alone. Net evidence favors possible formulation-specific short-term effects, not dependable relief from the species alone.

Magnitude: Adjusted breath-gas concentrations were 96.7 versus 142.5 parts per billion for G60 plus inulin versus placebo, and 115.7 versus 142.5 for G60 alone versus placebo; the latter difference was not statistically significant. The Oral S1 trials described above additionally found reduced odor gases in orthodontic patients; this does not resolve differences between strains and settings.

Cavity Prevention with an Inactivated Preparation

A 140-child randomized open-label trial found fewer new cavities after heat-inactivated HM6-containing tablets. Xylitol (a sugar alcohol) and the unmatched additional tablet intervention prevent attribution to bacteria alone. Evidence is indirect for live supplements and adult cavity prevention.

Magnitude: The reported difference between group percentages of children developing new cavities was 13.96 percentage points over one year; this applies to the tested pediatric formulation.

Blood Lipid Improvement ⚠️ Conflicted

UBL S22 research found favorable lipids, but Ls-33 research found no benefit. UCC118 in gestational diabetes (diabetes arising during pregnancy) modestly affected cholesterol. Different strains and populations prevent direct equivalence; overall, reliable lipid improvement by generic L. salivarius remains unestablished.

Magnitude: In gestational diabetes, low-density lipoprotein cholesterol (cholesterol carried in particles associated with artery disease) rose by 0.08 versus 0.31 mmol/L, probiotic versus placebo.

Glucose Control from Mixtures

A pediatric diabetes trial, involving manufacturer Bioflag, and an adult 14-strain trial reported improved glucose measures. Mixtures prevent species attribution; UCC118 research found no glucose benefit in gestational diabetes. Commercial involvement and mixed preparations limit interpretation; independent L. salivarius efficacy remains unestablished.

Magnitude: The mixture group’s HbA1c (glycated hemoglobin, a measure of average blood glucose) fell from 9.3% to 8.5% over six months; controls remained at 9.5%. The adult mixture trial reported a 0.44-percentage-point reduction over 24 weeks. The UCC118 trial reported identical post-treatment fasting glucose, 4.65 mmol/L, in both groups.

Function and Nutrition in Frail Older Adults

An uncontrolled nursing-home study associated MP101 with better daily function and nutritional scores. Recovery from COVID-19 (coronavirus disease) and concurrent care could explain change; cognition did not improve. These residents differ substantially from active older adults seeking prevention.

Magnitude: The Barthel daily-function score rose from 36 to 42 and the nutritional assessment score from 20.70 to 22.63 over four months; no control group established an attributable effect.

Knee Symptom Relief ⚠️ Conflicted

A 108-person trial, conducted by Megmilk Snow Brand-affiliated investigators, found small unadjusted SBT2687 symptom differences. They disappeared after adjustment for baseline scores. Proposed gut–joint immune effects therefore remain a hypothesis, and the net clinical result is inconclusive.

Magnitude: Pain changed by −2.9 versus −1.7 points on the reported visual rating scale over 12 weeks; baseline-adjusted comparisons were not statistically significant.

Reduced Reactivity to Sad Mood from a Mixture

An eight-strain trial included W24 and manufacturer Winclove investigators, a commercial interest. It measured responses to sad mood in 40 healthy adults, not diagnosed depression or prevention. The mixture cannot isolate this species; gut–brain signaling remains a proposed mechanism.

Magnitude: The mixture improved cognitive reactivity to sad mood after four weeks; the retrieved abstract gives no numerical score difference or species-attributable estimate.

Vaginal Health from Mixtures

A two-strain pilot, involving commercial firm CTCBIO, reported improved perceived well-being within the mixture group. A vaginal-tablet trial reported improvements in bacterial vaginosis (vaginal bacterial imbalance). Mixtures, different administration routes, and limited comparisons prevent attribution to this species or broad prevention claims.

Magnitude: Perceived well-being improved over three weeks among 26 completing pilot participants; the retrieved abstract provides no numerical between-group difference. After eight days of the three-species vaginal tablet, 32% restored normal flora and 47% improved microscopic bacterial-balance scores. These categories describe a mixture’s response and do not establish isolated-strain efficacy.

Rheumatoid Arthritis Control from a Mixture

A 100-patient trial tested BL2201 with two other bacteria alongside disease-modifying medicines for rheumatoid arthritis (inflammatory joint disease). Disease activity, pain, disability, and medication use improved. The mixture and concurrent treatment prevent attribution to this species; evidence concerns diagnosed disease.

Magnitude: The probiotic group’s 28-joint disease-activity score reached 2.3 after 12 months; controls returned toward baseline activity. This measures the entire add-on regimen, not an isolated-strain effect.

Lupus Disease Activity from a Mixture

A 50-patient trial tested nine bacteria plus fermentable fiber alongside treatment for lupus (an immune disease affecting multiple organs). Disease activity improved within the mixture group. Within-group change and the multicomponent preparation limit causal and species-specific interpretation.

Magnitude: Disease-activity scores declined after two months in the mixture group; the available abstract reports no numerical score change or between-group effect estimate.

Ulcerative Colitis Control from a Mixture

A 60-patient clinical study compared mesalazine alone with mesalazine plus three bacterial species for ulcerative colitis (inflammation and ulcers in the large intestine). Clinical response favored the mixture over two years. Study design and combined treatment prevent attribution to L. salivarius alone.

Magnitude: Modified Mayo disease-activity scores favored combination treatment through two years; the available abstract gives no numerical between-group score difference.

Abdominal Pain During Diverticulitis Treatment from a Mixture

An 84-patient randomized study tested LA302 with two other bacteria alongside antibiotics for acute uncomplicated diverticulitis (inflamed colon pouches). Pain improved faster and hospitalization was shorter. Multiple ingredients and the absence of a matched placebo prevent species attribution; findings concern active disease treatment.

Magnitude: Pain scores decreased by 4.06 versus 2.79 points on day three, and hospitalization averaged 89 versus 101 hours, mixture plus antibiotics versus antibiotics alone. The study does not establish prevention of diverticulitis or an independent LA302 effect.

Diarrhea Reduction ⚠️ Conflicted

An eight-strain pediatric trial, involving manufacturer Winclove, reduced overall diarrhea but not its stricter antibiotic-associated endpoint. A systematic review reports benefit with CECT5713 infant formula, whereas the primary abstract reports unchanged clinical parameters. Mixtures and inconsistent infant reporting leave species-attributable prevention uncertain.

Magnitude: Overall diarrhea risk was 35% lower with the mixture; the stricter antibiotic-associated outcome was 19% lower but statistically inconclusive. Analysis included 313 children, with supplementation continuing seven days after antibiotics. The infant-formula review provides no numerical diarrhea effect estimate in its abstract.

Respiratory Infection Prevention ⚠️ Conflicted

A systematic review reports fewer respiratory symptoms with CECT5713 infant formula. However, the 80-infant primary abstract states clinical parameters did not differ, and an athlete trial was negative. Different populations and inconsistent reporting leave infection prevention unestablished.

Magnitude: Symptomatic respiratory illness affected approximately 58% versus 59% of athletes over 16 weeks, probiotic versus placebo. The infant primary abstract provides no numerical respiratory effect estimate; its six-month formula study does not establish benefit in adults.

Improved Sleep Quality from a Mixture

A four-week trial of OMNi-BiOTiC STRESS Repair, containing W24 and eight other strains, found better subjective sleep. Winclove supplied products, a commercial interest. Gut–brain signaling is proposed; 94 of 130 randomized adults were analyzed, limiting certainty. The mixture cannot establish species-specific efficacy.

Magnitude: The Pittsburgh Sleep Quality Index (a questionnaire measuring sleep quality) favored the mixture by an estimated 1.15 points after four weeks. Final mean scores were 6.8 versus 7.7 with placebo; lower scores indicate better sleep. Quality of life and perceived stress did not improve.

Cognitive Performance from a Mixture

A trial in 61 people with Parkinson’s disease (a movement disorder) tested nine strains including W24. A secondary thinking-and-memory score improved, while the primary anxiety outcome did not. The small secondary finding cannot identify this species’ contribution or establish prevention of cognitive decline in healthy adults.

Magnitude: The adjusted Montreal Cognitive Assessment score favored the mixture by 1.1 points after 12 weeks. Depression, constipation, and movement symptoms did not differ significantly from placebo.

Weight Management from Mixtures ⚠️ Conflicted

A 90-adult trial, involving manufacturer Unique Biotech, reported weight reduction with UBLS-22 plus five other bacteria and fiber. A 48-person surgical trial, involving Sanprobi investigators, found no added benefit from a W24 mixture. Different formulations and settings leave species-attributable weight benefit unestablished.

Magnitude: The UB0316 trial reported a 95% confidence interval (range expressing estimate uncertainty) of −1.16 to −0.50 kg for the weight difference versus placebo after 12 weeks; 71 participants completed follow-up. The surgical trial found no added weight-loss benefit through six months.

Persistent Hives Relief from a Mixture

An uncontrolled study added LS01 and Bifidobacterium breve BR03 to allergy medicines in adults with persistent hives. Most completers did not improve. The mixture, continuing treatment, and absence of a placebo group prevent attributing improvement to this species or assuming benefit for other allergic conditions.

Magnitude: Among 38 evaluable patients after eight weeks, nine had mild improvement, one substantial improvement, and one complete remission; 27 had none. Fourteen of the original 52 participants discontinued treatment.

Fewer Recurrent Childhood Middle-Ear Infections

A PS7 pilot, involving Casen Recordati and Probisearch-linked investigators, followed children with recurrent middle-ear infections. Bacterial antagonism offers a plausible mechanism. Historical comparison and nonrandomized contemporaneous observations cannot establish causation; the result does not demonstrate adult infection prevention.

Magnitude: In 61 completers, infection episodes were 84% fewer during six months of supplementation than during the preceding six months. Natural improvement with age, season, and regression toward usual episode frequency could contribute.

Infant Colic Relief from a Mixture

An 87-infant open-label trial compared an Ls-33-containing bacterial mixture plus fiber with simethicone for colic (prolonged infant crying). Some crying measures favored the mixture. Lack of blinding and multiple ingredients limit attribution; these infant findings do not establish an adult health benefit.

Magnitude: After four weeks, at least halving crying days occurred in 72% versus 18%, and at least halving evening crying duration in 85% versus 39%, mixture versus simethicone. The number of daily crying phases did not differ significantly.

Fewer Childhood Asthma Attacks from a Mixture

A randomized trial of LS01 plus Bifidobacterium breve B632 found fewer asthma attacks, plausibly through gut–lung immune effects. Probiotical researchers participated, creating a commercial conflict. Analysis of 422 completing children cannot isolate this species or establish adult benefit; existing asthma treatment continued.

Magnitude: At least one attack occurred in 19/212 children receiving the mixture versus 50/210 receiving placebo over 16 weeks: 9.0% versus 23.8%. Attack duration and medication intensity did not differ significantly.

Fewer Inflammatory Acne Lesions from a Mixture

A 114-person trial tested three bacteria including LS03, botanical extracts, their combination, and placebo for acne. Investigators worked for Giuliani and Probiotical, commercial interests. Lesion counts improved with the bacterial mixture; multiple ingredients prevent species attribution, and the combined product produced the largest change.

Magnitude: Superficial inflammatory lesions decreased by 38.89% with the probiotic mixture, 56.67% with probiotics plus botanical extracts, and 10.00% with placebo over eight weeks.

Communication and Behavioral Function from Mixtures

A 61-child autism study reported communication and behavioral improvements; investigators included manufacturer Probiotical. A 15-child fragile X syndrome study (an inherited developmental condition) reported similar signals. Mixtures, substantial attrition in the autism study, and absent controls in the latter prevent species attribution or extrapolation to adult enhancement.

Magnitude: In the uncontrolled fragile X study, communication and adaptive-behavior scores improved by 1.7 and 1.3 points over 12 weeks, respectively. The autism crossover study used three-month treatment periods; neither study establishes an isolated-strain effect.

Speculative 🟨

Preservation of Bone Strength

Mouse and rat experiments suggest reduced hormone-deficiency bone loss through altered bone-cell metabolism or bacterial vesicles (small membrane particles). Human associations do not establish that supplementation prevents fractures or preserves bone density.

A 56-person dialysis trial tested an LS159-containing mixture for six months, reducing indoxyl sulfate, a bacterial toxin. This biomarker change does not establish improved kidney function, fewer cardiovascular events, or species-specific benefit.

A 61-adult liver-disease trial combined an antibiotic with a bacterial mixture containing this species. Ammonia and an exploratory neurological score improved; these unvalidated measures establish neither fewer hospitalizations nor a species-specific clinical benefit.

Longer Life and Slower Biological Aging

Worm and intestinal-aging research suggest mechanisms; the latter involves commercial firm AIage. A mixture trial reported less telomere shortening (chromosome-end erosion), an unvalidated aging marker. Neither species-attributable effects nor longer human life were established.

Cancer Prevention and Systemic Protection

The REN cancer review covers preclinical experiments. Proposed immune, liver, and pathogen-defense mechanisms do not establish cancer prevention, cardiovascular-event reduction, or broadly enhanced resistance to infection in healthy adults.

A seven-person UCC118 crossover experiment changed an exercise-related sugar-permeability test. This unvalidated surrogate does not establish fewer digestive symptoms, better performance, or faster recovery.

A V4II-90 trial, involving commercial firms Probisearch and Casen Recordati, increased clearance of group B streptococci (bacteria causing newborn infections). Clearance alone establishes neither infection prevention nor replacement of established maternity measures.

The UCC4331 bowel-symptom trial did not show the symptom benefit observed with its separate Bifidobacterium comparator. This is a measured negative outcome, not merely missing research.

Benefit-Modifying Factors

  • Strain and formulation: PS2, LS01, WB21, UCC118, and CECT30632 are not interchangeable. Live capsules, oral-contact tablets, and heat-inactivated products create different exposures; mixtures do not identify individual-strain effects.
  • Baseline measurements: Eczema severity, uric acid, gum inflammation, and diagnosed oral malodor define the studied problems. No validated stool-abundance threshold identifies a deficiency of this species or predicts who benefits.
  • Existing conditions: Benefits in eczema, recurrent gout, infertility, or lactation do not establish enhancement in adults without those conditions. Concurrent dental treatment, dienogest, or assisted reproduction can be essential to the tested regimen.
  • Sex and reproductive status: Mastitis and endometriosis evidence concerns women; the fertility trial treated both partners. Reliable sex-specific response differences for oral, intestinal, or metabolic outcomes have not been demonstrated.
  • Age: Childhood allergy and cavity findings are indirect for adults. Healthy-older-adult WB21 research found no improvement in gum bleeding or breath gases; uncontrolled frailty findings cannot establish preventive benefit in active older adults.
  • Genetics: No clinically validated human genetic variant currently selects a strain or predicts benefit. Bacterial strain genetics have more direct relevance to these studies than consumer host-genetic tests.

Potential Risks & Side Effects

Short trials generally report good tolerance, including the CECT5713 healthy-adult trial. Small samples and short follow-up cannot establish the absence of rare or delayed harms. The WebMD supplement monograph identifies gastrointestinal discomfort, allergy, and infection concerns; attribution is qualified below.

High 🟥 🟥 🟥

No adverse outcome reaches High: replicated controlled human trials have not demonstrated a consistent excess of a specific harm from this species.

Medium 🟥 🟥

No species-attributable harm reaches Medium: invasive-infection and critical-illness mixture observations are indirect for this species, while small trials do not establish an excess gastrointestinal-event rate.

Low 🟥

Death and Bowel Injury During Severe Pancreatitis

In PROPATRIA, a six-organism mixture containing this species increased deaths and bowel ischemia (injury from insufficient intestinal blood flow) during severe acute pancreatitis (sudden pancreatic inflammation). Tube feeding and critical illness distinguish this setting; the trial establishes mixture-level harm, not independent causation by this species.

Magnitude: Deaths occurred in 24/152 versus 9/144 patients, and bowel ischemia in 9/152 versus 0/144, probiotic mixture versus placebo. Eight bowel-injury cases were fatal; these are hospital-treatment results, not estimated risks for healthy supplement users.

Gastrointestinal Discomfort

Gas, altered stool consistency, or abdominal discomfort can accompany probiotic products; added inulin or sugar alcohols may contribute. The G60 trial reported mild transient effects in all groups, while PS2 research found comparable gastrointestinal tolerance. A species-attributable excess is unestablished.

Magnitude: Not quantified in available studies. The cited reports do not establish an attributable excess of gas or discomfort from L. salivarius over control ingredients.

Invasive Infection in Susceptible Hosts

A hospital cohort identified L. salivarius bloodstream infection, chiefly within a population with serious underlying illness. Bacteria may cross damaged barriers or contaminate catheters (tubes placed in blood vessels). The organism can cause disease in vulnerable hosts, but supplement causation and healthy-user incidence are unestablished.

Magnitude: L. salivarius accounted for 21 of 89 selected patients with lactobacillus bloodstream infection. This is a case-series composition, not a 24% infection risk among supplement users.

Allergy to Product Ingredients

A probiotic-product case report documented anaphylaxis (a potentially life-threatening allergic reaction) to milk protein. This was not evidence that L. salivarius itself caused allergy. The relevant risk is ingredient-specific and applies when a formulation contains the allergen, including residual production ingredients.

Magnitude: Not quantified in available studies. Case reports of other probiotic formulations do not provide an incidence for L. salivarius products.

Reduced Response to Cancer Immunotherapy ⚠️ Conflicted

Zhou et al. associated this organism with poor response in esophageal cancer (cancer of the swallowing tube); Zhang et al. found the opposite association in gastrointestinal cancers. Different metabolites and cancer settings may explain disagreement. Net evidence is conflicting and establishes neither benefit nor harm from supplementation.

Magnitude: Not quantified in available studies. Neither study estimates a supplement-attributable effect on cancer-treatment response.

Speculative 🟨

Enhanced Pathogen Activity in Experimental Models

Cell and mouse experiments found that L. salivarius and its metabolites enhanced Staphylococcus aureus (a potential pathogen) attachment and toxicity. Li et al. did not establish harm from human supplementation.

Transfer of Undesirable Bacterial Traits

The species safety review identifies strain-level safety gaps. Transferable antibiotic-resistance genes are a mechanistic manufacturing concern; clinical harm from gene transfer by the reviewed supplements has not been demonstrated.

Strain-Dependent Tooth Decay

In a rat experiment, LS1952R adhered to teeth and caused cavities. A human tablet study found no salivary-acidity difference; human supplement-attributable cavity risk remains unestablished.

Risk-Modifying Factors

  • Immune function and illness: Cancer treatment, major immune suppression, critical illness, and damaged intestinal barriers increase concern for invasive infection. Hospital infection observations do not quantify risk for otherwise healthy adults.
  • Baseline findings: Unexplained fever, active infection, severe intestinal inflammation, or an indwelling vascular catheter changes the safety context. There is no screening blood or stool threshold validated to certify probiotic safety.
  • Age: Frailty and associated illnesses matter more than chronological age alone. Safety experience in selected older adults does not establish safety in hospitalized or severely debilitated older patients.
  • Sex and pregnancy: No general sex difference in adverse-event susceptibility is established. Selected pregnancy trials provide reassuring short-term evidence for their strains; that reassurance is not transferable to every product or high-risk pregnancy.
  • Genetics and allergy: No validated human genetic test predicts adverse effects. A documented ingredient allergy is directly relevant; suspected genetic histamine-handling differences do not establish a strain-selection algorithm.
  • Cancer treatment: Opposing immunotherapy associations concern patients with different cancers and bacterial metabolites. No stool-abundance threshold or supplement dose predicts benefit or harm; cancer-free adults were not studied for this outcome.
  • Product composition: Milk, soy, other microbes, fermentable fibers, and sugar alcohols can change tolerability. A higher total viable count does not guarantee either greater benefit or lower risk.

Key Interactions & Contraindications

  • Antibiotics (amoxicillin, doxycycline) — caution: These medicines may reduce viable probiotic exposure depending on strain susceptibility. Two-hour separation is a pragmatic convention, not a validated L. salivarius efficacy rule; it does not eliminate antibiotic exposure in the intestine.
  • Immune-suppressing medicines (tacrolimus, mycophenolate, high-dose prednisone) — caution: Reduced host defenses can increase invasive-infection susceptibility. Cytotoxic treatment (cell-killing therapy, such as cyclophosphamide) adds similar concern; a change in drug concentration is not established.
  • Cancer immunotherapy (pembrolizumab, nivolumab) — caution: These anti-PD-1 medicines (treatments that release an immune brake) may interact with bacterial immune effects described above. Studies report opposing treatment-response associations; no supplement-causation estimate or validated timing separation exists.
  • Oral antiseptics (chlorhexidine, cetylpyridinium) — caution: These mouth rinses may inhibit oral probiotic organisms. No clinical study establishes an optimal separation interval; concurrent antiseptic use changes the exposure tested by an oral-contact product.
  • Over-the-counter medicines — monitor: No specific interaction with pain medicines (acetaminophen, ibuprofen) or antacids (calcium carbonate) is established. Altered acidity could affect bacterial survival, but clinically important changes in these medicines’ effects have not been demonstrated.
  • Fiber supplements — monitor: Inulin and fructo-oligosaccharides (fermentable carbohydrates used as prebiotics) may add gastrointestinal symptoms and potentially modify efficacy. The G60-plus-inulin trial does not establish broad synergy with all strains.
  • Other probiotic supplements — monitor: Combining products can duplicate organisms, increase fermentable ingredients, and obscure the cause of symptoms. Clinical interaction studies do not establish an optimal mixture or an added benefit from stacking products.
  • Disease treatment — caution: Substituting a probiotic for needed dental care, urate-lowering treatment, antibiotics, or maternity infection prevention can leave disease undertreated. The studies of supplementation do not establish such substitutions as equivalent.

Populations who should avoid Lactobacillus salivarius:

  • Individuals with a known allergy to the exact product or its ingredients: an absolute contraindication to that formulation because of potentially severe allergy.
  • People with predicted severe acute pancreatitis: the hospital trial found increased mortality and bowel injury with a mixture containing this species. This clinical severity category is a specific exclusion from probiotic supplementation.
  • People with severe immune suppression, active intensive-care illness, an indwelling central venous catheter, or major intestinal-barrier disruption: live-organism use outside a specialist-supervised indication presents an unfavorable infection-risk context. No species-specific numerical immune-cell cutoff has been validated.
  • Premature infants outside an explicitly supervised neonatal protocol: this population is outside the adult review and has distinct live-probiotic infection risks.

These precautionary exclusions are based on host vulnerability and the supplement monograph, not on a validated risk calculator. Pregnancy or older age alone is not an absolute contraindication.

Risk Mitigation Strategies

  • Exact-strain identification: Matching the strain, route, and preparation to the clinical question reduces ineffective substitution and unwarranted exposure. Species-only labeling cannot demonstrate equivalence to PS2, LS01, or WB21 research.
  • Ingredient screening: Checking declared allergens, culture-media residues, inulin, and sugar alcohols addresses allergy and gastrointestinal intolerance. Independent identity and contamination testing addresses exposure to unintended organisms.
  • Early tolerance review: Recording new abdominal discomfort, gas, or stool changes during the first one to two weeks helps distinguish intolerance from the intended response. No trial establishes a species-wide dose-escalation schedule.
  • Severe-illness exclusion: Avoiding probiotic supplementation during predicted severe acute pancreatitis addresses the mixture-associated mortality and bowel-injury signal. This finding does not supply a safe lower dose or an alternative timing schedule.
  • Infection surveillance: Fever, shaking chills, or rapidly worsening illness can signal invasive infection. Clinical assessment and withholding further live-organism exposure are risk-management measures, particularly with immune suppression or a catheter; no species-specific fever threshold is validated.
  • Oncology context: Documenting probiotic products during cancer immunotherapy allows treatment-team review of the uncertain response interaction. Opposing research findings leave the direction unresolved; no validated dose reduction, timing separation, or screening test eliminates this uncertainty.
  • Time-limited evaluation: A predefined reassessment after the indication’s studied interval, commonly four to eight weeks for oral or intestinal outcomes, limits indefinite exposure without observable benefit.
  • Preserving established care: Keeping dental hygiene and condition-specific treatment stable reduces the risk of undertreatment and makes any added probiotic effect easier to interpret.

Therapeutic Protocol

  • Protocol status: No established practitioner-standard regimen exists for healthspan or lifespan extension. The following are research regimens, not a unified longevity prescription; different strains address different conditions.
  • Oral-health regimen: Shimauchi and colleagues studied WB21 tablets containing 670 million colony-forming units (a measure of viable bacteria) three times daily, about 2 billion daily, for eight weeks. Study.
  • Oral-contact timing: WB21 studies used tablets after meals, allowed to dissolve in the mouth; the older-adult study specified after brushing. No comparison establishes superiority of morning versus evening dosing. Protocol.
  • Intestinal regimen: The healthy-adult CECT5713 trial used 200 million viable bacteria in a daily oral capsule for four weeks. This is a strain-specific study dose, not a minimum effective dose for other products. Study.
  • Mastitis-prevention regimen: The multicountry PS2 trial used approximately 1 billion viable bacteria once daily from gestational week 35 through 12 weeks after delivery. Research addressed prevention; established mastitis still received clinical assessment and treatment. Study.
  • Fertility regimen: Both partners received CECT5713, 3 billion viable cells once daily, before and during the first assisted-reproduction cycle; women continued through the first 12 pregnancy weeks. This was a specialist fertility protocol. Study.
  • Gout regimen: The CECT30632 pilot used 1 billion viable bacteria daily for six months, with treatment adjusted to clinical need. Its small comparison does not establish a replacement for optimized urate-lowering therapy. Study.
  • Competing approaches: Dental research studies supplementation alongside hygiene or periodontal (gum-supporting tissue) care; integrative discussions propose broader microbiome support. Neither approach supplies a validated longevity dose, and broader multi-strain protocols cannot identify the necessary L. salivarius component.
  • Half-life and divided doses: No conventional human half-life is established. Daily capsules and three-times-daily oral-contact tablets reflect different trial designs; no head-to-head study determines whether splitting an equal dose improves efficacy.
  • Genetics and sex: No validated host-genetic adjustment or sex-based dose rule exists. Reproductive indications have population-specific schedules rather than general male–female dosing differences.
  • Age, biomarkers, and disease: No dose adjustment is established for healthy older age or low stool abundance. Disease severity defines the goal; frailty, immune suppression, and serious gastrointestinal disease alter suitability rather than supplying a titration formula.

Discontinuation & Cycling

  • Duration: Most studies evaluate finite courses lasting weeks to months. Lifelong supplementation has not been shown to preserve benefit or extend life.
  • Withdrawal: No established withdrawal syndrome is reported. Symptoms may recur if an effect depends on continuing exposure; that is distinct from physiological dependence.
  • Tapering: No tapering protocol is established or biologically required for these probiotic preparations. Research generally stops the product at the end of the assigned course.
  • Cycling: There is no controlled evidence that scheduled cycling maintains efficacy or prevents tolerance. Deliberate breaks can document persistence of a perceived effect but are not an evidence-based enhancement strategy.

Sourcing and Quality

  • Identity: A useful label specifies the full species, exact strain identifier, viable count per daily dose at expiry, and storage requirements. A blend’s total bacterial count does not reveal the amount of L. salivarius.
  • Independent testing: Relevant third-party or accredited-laboratory checks include strain identity, viable count, unintended organisms, and contaminants. Safety documentation can assess transferable resistance genes; a generic quality logo alone does not establish clinical equivalence.
  • Formulation: Oral-health studies often require contact with the tongue and gums. Swallowed capsules, heat-killed tablets, and home-fermented preparations cannot be substituted on the basis of the species name alone.
  • Research product example: Wakamoto’s Minna No Zendamakin WB21 Tablet was used in published dental research. Naming the research supplier does not verify current retail batches, international availability, or the formulation of a differently branded product.
  • Viability and allergens: Storage conditions follow the specific stability data and label, including refrigeration when required. Expired or heat-exposed products may lose viability; production using dairy or soy materials makes allergen disclosure relevant even in apparently dairy-free formats.

Practical Considerations

  • Time to effect: Oral studies usually assess two to eight weeks, eczema studies eight to sixteen weeks, and fertility or gout studies several months. No time-to-benefit estimate exists for longevity.
  • Common pitfalls: Confusing L. salivarius with Streptococcus salivarius K12 or M18, omitting the strain identifier, attributing mixed-product effects to one organism, or treating stool abundance as proof of benefit can misdirect interpretation.
  • Regulatory status: In the United States, these products are generally marketed as dietary supplements. They are not approved as treatments or longevity medicines; regulation and permitted claims differ elsewhere. The supplement monograph describes this distinction.
  • Access and cost: Standard probiotic supplements are widely available, but exact research strains and formulations may require regional sourcing. Price and total bacterial count are poor substitutes for matched evidence; no cost-effectiveness analysis establishes a longevity return.
  • Attribution: A defined symptom or clinical measurement is more informative than nonspecific feelings of improved health. Simultaneous changes in diet, hygiene, medication, or several supplements make individual attribution difficult.

Interaction with Foundational Habits

  • Sleep: A W24-containing mixture trial improved subjective sleep after four weeks; species-specific effects remain unestablished. Gut–brain signaling is proposed. Winclove supplied products, and 36 of 130 randomized participants were excluded from analysis. Stable sleep schedules help interpret symptom changes; the study did not establish lasting benefit.
  • Nutrition: A direct ecological interaction is plausible because diet supplies bacterial substrates. Inulin modified one oral formulation’s result, but also can cause gas. Ordinary fiber-containing foods remain distinct from an exact-strain intervention; dietary restriction or unusual fermentation regimens have no established potentiating role.
  • Exercise: A small UCC118 study suggests an effect on an intestinal-permeability test during strenuous running, without demonstrated performance benefit. The athlete respiratory trial was negative. No evidence establishes a need to time dosing around training or shows blunting of strength adaptation.
  • Stress management: Gut–brain signaling offers an indirect rationale, and a multi-strain trial measured responses to sad mood. No isolated-strain trial establishes added benefit with meditation, breathing exercises, or psychotherapy; these practices are not substitutes for a measurable probiotic endpoint.

Monitoring Protocol & Defining Success

Baseline assessment documents the intended outcome, relevant diagnosis, medications, product ingredients, allergies, bowel habits, and recent infections. Dental examination or eczema scoring applies when those conditions define the goal; routine blood tests are not established prerequisites in healthy adults. The selected measure provides a consistent reference for interpreting changes during supplementation.

Tolerance can be reviewed at one to two weeks and oral or intestinal outcomes at four to eight weeks. Other indications follow their study interval. No laboratory panel or commercial microbiome range is validated for monitoring this species. Success means reproducible clinical improvement without adverse effects; bacterial detection alone is insufficient.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Oral inflammation and pocket depth No probiotic-specific optimal range; track change from individual baseline Measure oral outcome Same dental examiner and method at baseline and 4–8 weeks; periodontal treatment goals depend on diagnosis
Eczema severity score No probiotic-specific target; track change from baseline Measure skin outcome SCORAD means SCORing Atopic Dermatitis, a validated symptom-and-sign scale; baseline and 8–16 weeks when relevant
Serum urate, only for established gout No probiotic-specific functional range; track change from baseline against the treating clinician’s disease target Follow gout biology Baseline and condition-specific follow-up; the pilot’s decline to 7.90 mg/dL did not establish disease control
Blood count, chemistry, or inflammatory tests No established monitoring target for routine supplementation; track clinically indicated abnormalities Investigate illness Not a routine longevity panel; testing is prompted by symptoms or underlying disease
Stool or oral species abundance No established healthy or optimal L. salivarius range; clinical change is the relevant endpoint Limited research utility Commercial reference intervals do not establish deficiency, efficacy, or safety; routine serial testing has no demonstrated value
  • Symptoms: Track breath concerns, bowel frequency, skin discomfort, or the selected symptom consistently.
  • Function: Record daily comfort and ability to perform usual activities.
  • Adverse effects: Record new digestive symptoms, rash, fever, or worsening illness.

Emerging Research

  • Depression in Parkinson’s disease: NCT05568498 is recruiting 60 adults for a W24-containing Ecologic BARRIER mixture versus placebo. University of British Columbia investigators assess depression using clinician-rated and self-reported scales at 13 weeks. Results could support or weaken mixture-level mood benefits without identifying W24’s contribution.
  • Recovery after neurosurgery: NCT07200518 is recruiting 110 adults for a W24-containing OMNi-BiOTiC Hetox mixture versus placebo. University Maribor investigators test four weeks of supplementation, with change in a validated disability score at three months as primary outcome. Findings would concern postoperative function and the mixture, not isolated-strain longevity effects.

  • Endurance-athlete trial: NCT07252778 reports recruitment of 30 athletes for a two-week crossover comparison of Sanprobi’s commercial W24-containing mixture versus placebo. Primary outcomes concern intestinal integrity, inflammation and microbial composition. Symptoms and exercise measures may help assess relevance, but biomarker changes alone would not demonstrate improved performance or an isolated W24 effect.
  • Multiple-sclerosis trial: NCT07168772 is recruiting 80 adults with multiple sclerosis (immune damage to the brain and spinal cord) for six months of an LA302-containing mixture or placebo. Hospital-sponsored research uses Pileje’s commercial Lactibiane iki product. Its immune-cell endpoint cannot establish reduced disability or isolate this species.
  • Dialysis biomarker studies: NCT07443280 and NCT07461233 each report recruitment of 30 dialysis patients receiving an LS159-containing mixture without a control group. Primary endpoints include bacterial toxins, microbial composition, inflammation or intestinal permeability. These related records should not be assumed to represent independent cohorts; neither design isolates this species or proves clinical benefit.
  • Depression and metabolic syndrome: NCT06765057 studies 60 adults with depression and metabolic syndrome (cluster of blood-pressure, glucose and lipid abnormalities), using Winclove’s W24 mixture or placebo alongside antidepressants for 12 weeks. Winclove receives anonymized data. Mood and metabolic outcomes are primary; the September 2025 update predates elapsed completion estimates, leaving progress uncertain.
  • Depression trial: NCT07786285 plans 200 adults receiving stable antidepressants and a W24-containing mixture or placebo for 12 weeks; depression severity is primary. The registry reports “not yet recruiting.” Industry collaborator Institut AllergoSan Pharma GmbH has a commercial interest. Results would concern the mixture, not isolated W24.
  • Sleep replication: NCT05836168 remains marked “active, not recruiting,” but Horvath et al., 2026 published results: 130 randomized, 94 analyzed after four weeks. Winclove supplied products. The modest W24-mixture finding and attrition make independent replication and durability relevant; neither this trial nor its stale registry establishes a species-specific effect.
  • Fertility microbiota trial: NCT06122207 is recruiting 120 participants to evaluate PS11610, with vaginal microbial imbalance as a primary endpoint. Sponsor Probisearch has a commercial interest. This is a different strain from the completed CECT5713 trial; microbial normalization would not alone establish more live births.
  • Healthy-adult LS97 study: NCT06886724 plans 40 adults and eight weeks of LS97, primarily assessing stool microbial composition. Manufacturer Wecare is the sponsor. The record remains “not yet recruiting,” last updated March 2025, despite elapsed estimated dates; current progress is uncertain.
  • Liver and metabolic trial: NCT07400367 is recruiting approximately 80 adults with metabolic fatty liver disease. AP-32 is one of four strains added to lifestyle intervention; liver stiffness at 12 weeks is primary. Results could strengthen or weaken formulation-level claims but cannot isolate AP-32.
  • Intestinal aging mechanism: Cao et al., 2026 link a bacterial metabolite to cellular repair in aging models, alongside human observational comparisons. Human supplementation outcomes, including function and safety, would determine whether this mechanistic rationale translates to healthspan; no lifespan benefit is established.
  • Cancer-treatment response: Zhou et al., 2026 and Zhang et al., 2026 reported opposing patient associations and experimental effects. Different cancer settings, strains, and metabolites may determine direction. Supplementation trials could strengthen targeted treatment hypotheses or identify harm; retail-product effects remain unknown.
  • Fatigue research: NCT03773003 plans 150 participants and tests a mixture containing this species against placebo, assessing fatigue with validated questionnaires three months after chemotherapy. Saarland University sponsors it. The registry remains “recruiting,” last updated May 2025 despite elapsed completion estimates; mixture efficacy and current progress remain uncertain.
  • Clinical replication: The Ushizawa et al., 2026 knee trial illustrates why baseline adjustment can weaken apparently positive findings. Replication with prespecified patient-important outcomes could either substantiate targeted benefit or narrow the rationale for continued supplementation.

Conclusion

Lactobacillus salivarius contains strains with different properties. The strongest clinical evidence concerns selected preparations for preventing breast inflammation during breastfeeding and reducing eczema severity. Other findings concern fertility, gout, bowel frequency and condition-related quality of life. Oral and metabolic results are inconsistent. Mixture studies suggest additional benefits but cannot identify this species’ contribution. Relevance to adults pursuing health and longevity depends on existing conditions and goals.

Short-term tolerance is generally favorable. Digestive discomfort, ingredient allergies and infection susceptibility affect practical use. A hospital trial found increased deaths and intestinal injury with a mixture during severe pancreatic inflammation; this does not quantify risk for healthy supplement users. Cancer-treatment studies report opposing associations without establishing supplement effects. Strain identity, living-bacteria counts, formulation and other ingredients determine how closely products resemble the research.

Commercial involvement includes Danone Nutricia, Probisearch, Kerry, Glac, Bioflag, Puleva Biotech, Exeltis Germany, OTC Chemo, Winclove, CTCBIO, Cultech, AIage, Wakamoto, Unique Biotech, Sanprobi, Casen Recordati, Megmilk Snow Brand, Probiotical, Giuliani, Institut AllergoSan, Wecare and Shenzhen Xbiome Biotech; emerging trials also use Pileje products. These interests affect interpretation across the cited studies; Life Extension and Chris Kresser also sell supplements or training. Small samples, mixed preparations and incomplete safety reporting limit certainty. For proactive adults, potential benefit remains tied to specific conditions and preparations. Routine supplementation has not been shown to slow human aging or extend life.

Top - Benefits - Risks - Protocol